HYPR:NASDAQHyperfine, Inc. Analysis
Data as of 2026-05-19 - not real-time
$1.41
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Hyperfine, Inc. is trading at $1.41, comfortably above its 50‑day (1.34) and 200‑day (1.24) simple moving averages but still below the 20‑day SMA (1.56), indicating a short‑term pullback within a broader bullish trend. The RSI sits at 44, suggesting neutral momentum, while the MACD histogram is negative and the signal line is bearish, flagging potential downside pressure in the near term. Despite a volatile 30‑day price swing of nearly 80% and a high beta of 2.83, the stock benefits from a strong revenue surge of 83% YoY, gross margins projected at 50‑55%, and a cash balance of $40.8 M that dwarfs its $13.1 M debt load. Analyst sentiment is upbeat, with a "strong_buy" rating, a median price target of $2.00 and an implied upside of over 50%, reinforced by recent coverage initiations from BTIG and others. However, operating and net losses persist, free cash flow remains negative, and volume is trending down, underscoring the need for caution as the company ramps up sales and expands internationally.
Overall, the stock appears undervalued relative to its growth prospects, but investors must weigh the high volatility, cash‑burn profile, and execution risk tied to its expansion plans.
Overall, the stock appears undervalued relative to its growth prospects, but investors must weigh the high volatility, cash‑burn profile, and execution risk tied to its expansion plans.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price hovering near recent support around $1.26
- Negative MACD histogram and bearish signal line
- Decreasing trading volume indicating limited short‑term liquidity
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Robust 83% YoY revenue growth and expanding gross margins
- Analyst consensus strong‑buy with a $2.00 median target
- Projected upside of roughly 53% from current price
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- International expansion and new IDN partnership pipeline
- Guidance of $20‑22 M revenue with 50‑55% gross margin
- Strong cash position relative to debt providing runway for growth
Key Metrics & Analysis
Financial Health
Revenue Growth82.60%
Profit Margin-226.88%
P/E Ratio-4.1
ROE-89.78%
ROA-38.19%
Debt/Equity38.19
P/B Ratio3.3
Op. Cash Flow$-27707000
Free Cash Flow$-16274000
Industry P/E27.2
Technical Analysis
TrendBullish
RSI44.4
Support$1.26
Resistance$1.93
MA 20$1.56
MA 50$1.34
MA 200$1.24
MACDBearish
VolumeDecreasing
Fear & Greed Index89.18
Valuation
Target Price$2.17
Upside/Downside53.66%
GradeUndervalued
TypeBlend
Risk Assessment
Beta2.83
Volatility79.54%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.